AstraZeneca’s Soriot Open to Buying Immune-Therapy Company

Updated on

AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body’s immune response, Chief Executive Officer Pascal Soriot said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.